Fitusiran - Alnylam Pharmaceuticals

Drug Profile

Fitusiran - Alnylam Pharmaceuticals

Alternative Names: ALN-AT3; ALN-AT3SC; SAR-439774

Latest Information Update: 17 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Sanofi Genzyme
  • Class Antifibrinolytics; Antihaemorrhagics; Antisense RNA; Drug conjugates; Small interfering RNA
  • Mechanism of Action Antithrombin III inhibitors; Haemostasis stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A; Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemophilia A; Haemophilia B

Most Recent Events

  • 07 Feb 2018 Sanofi announces intention to submit regulatory applications in USA, European Union and Japan for Haemophilia A and Haemophilia B in 2020
  • 07 Jan 2018 Alnylam intends to assume full development and commercialisation responsibility for fitusiran-related development by mid-2018
  • 15 Dec 2017 Alnylam re-initiates enrolment in the phase III ATLAS-INH trial following the approval of risk mitigation measures, protocol amendments and other updated clinical materials in Haemophilia A and Haemophilia B in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top